| Title |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews
|
|---|---|
| Published in |
Cochrane database of systematic reviews, November 2013
|
| DOI | 10.1002/14651858.cd010567.pub2 |
| Pubmed ID | |
| Authors |
Philip J Wiffen, Sheena Derry, R Andrew Moore, Dominic Aldington, Peter Cole, Andrew SC Rice, Michael PT Lunn, Katri Hamunen, Maija Haanpaa, Eija A Kalso |
| Abstract |
Antiepileptic drugs have been used for treating different types of neuropathic pain, and sometimes fibromyalgia. Our understanding of quality standards in chronic pain trials has improved to include new sources of potential bias. Individual Cochrane reviews using these new standards have assessed individual antiepileptic drugs. An early review from this group, originally published in 1998, was titled 'Anticonvulsants for acute and chronic pain'. This overview now covers the neuropathic pain aspect of that original review, which was withdrawn in 2009. |
Twitter Demographics
The data shown below were collected from the profiles of 101 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 18 | 18% |
| United Kingdom | 15 | 15% |
| Canada | 6 | 6% |
| United States | 5 | 5% |
| Australia | 4 | 4% |
| Ecuador | 3 | 3% |
| Venezuela, Bolivarian Republic of | 2 | 2% |
| Netherlands | 2 | 2% |
| Italy | 2 | 2% |
| Other | 8 | 8% |
| Unknown | 36 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 81 | 80% |
| Practitioners (doctors, other healthcare professionals) | 13 | 13% |
| Scientists | 4 | 4% |
| Science communicators (journalists, bloggers, editors) | 3 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 481 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | <1% |
| Spain | 3 | <1% |
| Finland | 1 | <1% |
| Chile | 1 | <1% |
| Unknown | 473 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 75 | 16% |
| Student > Bachelor | 58 | 12% |
| Researcher | 52 | 11% |
| Student > Doctoral Student | 36 | 7% |
| Other | 35 | 7% |
| Other | 100 | 21% |
| Unknown | 125 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 180 | 37% |
| Nursing and Health Professions | 37 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 29 | 6% |
| Neuroscience | 19 | 4% |
| Psychology | 14 | 3% |
| Other | 60 | 12% |
| Unknown | 142 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 93. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 December 2022.
All research outputs
#427,213
of 24,362,308 outputs
Outputs from Cochrane database of systematic reviews
#775
of 12,900 outputs
Outputs of similar age
#3,448
of 218,343 outputs
Outputs of similar age from Cochrane database of systematic reviews
#15
of 238 outputs
Altmetric has tracked 24,362,308 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,900 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 34.2. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 218,343 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 238 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.